Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Vabysmo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Faricimab-Svoa (sold as Vabysmo), first approved Jan 28, 2022, with 3 new uses approved and 0 published complete response letters.
First approved: Jan 28, 2022
Applications: 1
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $2.40B
First approved in the EU: Sep 15, 2022
First approved in Japan: Mar 28, 2022
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 2 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
VabysmoDrugs with a new indication and a new dosage for the treatment of choroidal neovascularization associated with angioid streaks. · Chugai Pharmaceutical Co., Ltd. · May 19, 2025 · Review report
VabysmoA drug with a new indication and a new dosage for the treatment of macular edema following retinal vein occlusion. · Chugai Pharmaceutical Co., Ltd. · Mar 26, 2024
Vabysmo, new ingredientA drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization… · Chugai Pharmaceutical Co., Ltd. · Mar 28, 2022
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
